Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
Authors:
Open Access
- 30 March 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 9 (4) , 1017-1030
Abstract
Introduction Guselkumab, a novel interleukin-23p19 subunit monoclonal antibody, has been shown to effectively improve the diverse manifestations of active psoriatic arthritis (PsA) in two phase 3 trials (DISCOVER-1, DISCOVER-2). Serum concentrations of extracellular matrix (ECM) biomarkers at baseline and following treatment with guselkumab were evaluated in patients with active PsA, and the relationship of these biomarkers with baseline PsA characteristics and clinical response to guselkumab treatment was explored. Methods Serum samples were collected at weeks 0, 4, 24, and 52 from a selected subset (N = 260) of the 739 biologic-naïve patients with PsA treated with guselkumab 100 mg every 4 or 8 weeks or placebo in DISCOVER-2. Demographically matched healthy controls (N = 76) were used for comparison. The samples were analyzed for ECM biomarkers associated with collagen degradation (C1M, C2M, C3M, C4M, C6M, C10C) and collagen formation (PRO-C1, PRO-C2, PRO-C3, PRO-C4, PRO-C6). Results Baseline concentrations of collagen degradation biomarkers C1M, C3M, C4M, and C6M and collagen formation biomarkers PRO-C3 and PRO-C6 were significantly higher (i.e., ≥ 1.25-fold and false discovery rate adjusted p < 0.05) in PsA patients than in healthy controls. Serum C1M, C3M, C4M, and C6M levels declined from baseline in guselkumab-treated patients in both dosing regimens. In addition, guselkumab-treated ACR20 responders (≥ 20% improvement in American College of Rhematology response criteria) had significantly lower C1M levels than ACR20 nonresponders. Conclusion These data demonstrate that serum collagen biomarkers are elevated in patients with PsA compared with healthy controls and that treatment with guselkumab decreases levels of C1M, C3M, C4M, and C6M. Importantly, C1M serves as a biomarker that associates with improvement of joint signs and symptoms. Trial Registration ClinicalTrials.gov identifier: NCT03158285.Keywords
Funding Information
- Janssen Research and Development
This publication has 34 references indexed in Scilit:
- Psoriatic ArthritisNew England Journal of Medicine, 2017
- The minor collagens in articular cartilageProtein & Cell, 2017
- Sensitization and Serological Biomarkers in Knee Osteoarthritis Patients With Different Degrees of SynovitisThe Clinical Journal of Pain, 2016
- Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritisArthritis Research & Therapy, 2016
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic ArthritisArthritis & Rheumatology, 2016
- Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic SpondyloarthropathyThe Journal of Rheumatology, 2014
- Cartilage Turnover Reflected by Metabolic Processing of Type II Collagen: A Novel Marker of Anabolic Function in ChondrocytesInternational Journal of Molecular Sciences, 2014
- Serological identification of fast progressors of structural damage with rheumatoid arthritisArthritis Research & Therapy, 2013
- Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional studyRheumatology International, 2011
- Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—Increased serum CIIM in subjects with severe radiographic osteoarthritisClinical Biochemistry, 2011